Arcellx (ACLX) Competitors $66.24 -0.37 (-0.56%) Closing price 03:59 PM EasternExtended Trading$66.18 -0.05 (-0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACLX vs. SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, ROIV, RVMD, and VRNAShould you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Arcellx vs. Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Revolution Medicines Verona Pharma Summit Therapeutics (NASDAQ:SMMT) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Does the MarketBeat Community favor SMMT or ACLX? Summit Therapeutics received 245 more outperform votes than Arcellx when rated by MarketBeat users. However, 83.13% of users gave Arcellx an outperform vote while only 58.47% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes31458.47% Underperform Votes22341.53% ArcellxOutperform Votes6983.13% Underperform Votes1416.87% Do institutionals and insiders believe in SMMT or ACLX? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Comparatively, 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, SMMT or ACLX? Summit Therapeutics has a beta of -1.06, indicating that its share price is 206% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Is SMMT or ACLX more profitable? Summit Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Arcellx's return on equity of -8.28% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Arcellx -25.94%-8.28%-5.21% Which has higher earnings and valuation, SMMT or ACLX? Arcellx has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K21,817.41-$614.93M-$0.34-60.48Arcellx$76.81M48.25-$70.69M-$2.99-22.49 Does the media prefer SMMT or ACLX? In the previous week, Arcellx had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 19 mentions for Arcellx and 16 mentions for Summit Therapeutics. Arcellx's average media sentiment score of 1.19 beat Summit Therapeutics' score of 0.53 indicating that Arcellx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcellx 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SMMT or ACLX? Summit Therapeutics presently has a consensus price target of $35.09, suggesting a potential upside of 70.64%. Arcellx has a consensus price target of $111.33, suggesting a potential upside of 65.54%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.07 SummaryArcellx beats Summit Therapeutics on 11 of the 18 factors compared between the two stocks. Get Arcellx News Delivered to You Automatically Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACLX vs. The Competition Export to ExcelMetricArcellxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.71B$3.12B$5.60B$8.65BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-94.7333.7027.3320.13Price / Sales48.25475.70412.21156.99Price / CashN/A168.6838.2534.64Price / Book6.753.507.154.74Net Income-$70.69M-$72.35M$3.23B$247.88M7 Day Performance2.71%8.30%3.49%2.64%1 Month Performance16.42%22.83%12.92%9.95%1 Year Performance24.55%-16.08%32.15%15.33% Arcellx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACLXArcellx2.182 of 5 stars$66.24-0.6%$111.33+68.1%+23.1%$3.65B$76.81M-93.3580Positive NewsAnalyst RevisionSMMTSummit Therapeutics2.9218 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700,000.00-63.32110Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories1.1802 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.254 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.4132 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.1623 of 5 stars$8.69-1.1%$10.50+20.8%-14.0%$10.20B$14.33B-11.7437,000QGENQiagen3.135 of 5 stars$44.89-0.5%$48.42+7.9%+6.0%$9.98B$2.00B125.006,030BPMCBlueprint Medicines0.8504 of 5 stars$127.79+26.1%$125.69-1.6%+23.0%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.3179 of 5 stars$11.17+1.6%$17.50+56.7%+7.5%$7.97B$29.05M-74.46860RVMDRevolution Medicines4.1706 of 5 stars$40.65+3.2%$67.08+65.0%+5.3%$7.57B$742,000.00-11.32250VRNAVerona Pharma2.4557 of 5 stars$84.10+3.6%$82.13-2.3%+586.0%$6.82B$118.54M-43.8030Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies SMMT Competitors RDY Competitors ASND Competitors MRNA Competitors VTRS Competitors QGEN Competitors BPMC Competitors ROIV Competitors RVMD Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACLX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACLX Stock Free ACLX Stock Alerts